Epigenomics AG / Key word(s): Corporate Action
13.12.2013 19:49
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act):
Epigenomics AG sets conversion price
Berlin, Germany, December 13, 2013 - Epigenomics AG (ISIN: DE000A1K0516)
announces that its Executive Board today has set the conversion price of
the convertible bonds, the respective issuance of which has been published
in an ad hoc announcement dated December 3, 2013. As announced in the
rights offering, the conversion price was determined according to the
XETRA-volume weighted average quotation of Epigenomics' shares during the
period from Wednesday December 11, 2013 to Friday, December 13, 2013 (both
dates included) and equals EUR 5.87.
The convertible bonds in the aggregate principal amount of up to EUR
2,675,000.00 are currently being offered in a rights offering to those
shareholders of Epigenomics AG that held at least one single share in the
Company as of December 3, 2013 at an issue price of EUR 100,000 per bond
with a principal amount of EUR 107,000. The subscription period for the
Company's shareholders ends on December 18, 2013 at 24:00 CET. Convertible
bonds not subscribed for during the course of the rights offering by the
Company's shareholders will be acquired according to an agreement between
Epigenomics and an U.S. American institutional investor by such investor at
the same conditions as offered to shareholders.
Each convertible note will be convertible into 107,000 freely tradable
shares of Epigenomics' common stock against payment of a conversion premium
that equals the product of multiplying (A) the conversion price minus EUR
1.00 with (B) the number of shares to be issued upon conversion (i.e.
107,000). In the event of a conversion of individual or all bonds against
payment of a conversion premium, the Company may generate further gross
proceeds in the possible amount of up to EUR 13,027,250. Epigenomics has
certain further rights to require conversion upon maturity of the
convertible bonds or upon FDA approval of its lead product Epi proColon(R).
Epigenomics expects that the proceeds from the issuance of these bonds will
help to fund the business operations beyond the FDA approval of its lead
product, Epi proColon(R), a blood-based test for the detection of
colorectal cancer. Among others, certain market preparatory activities will
be funded by the proceeds from the offering.
Further information regarding the rights offering on the issuance of
convertible bonds were published on the Company's website
(www.epigenomics.com).
- End of Ad hoc -
Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
13.12.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
13. December 2013 - 0:00 (CEST)